REVIEW

547  Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives
Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M

568  Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies
Choi KKH, Sanagapalli S

587  Gut and liver involvement in pediatric hematolymphoid malignancies
Devarapalli UV, Sarma MS, Mathiyazhagan G

607  Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review

MINIREVIEWS

628  Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma

646  Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases
Akiyama S, Sakamoto T, Steinberg JM, Saito Y, Tsuichiya K

654  Colorectal cancer carcinogenesis: From bench to bedside
Currais P, Rosa I, Claro I

ORIGINAL ARTICLE

Basic Study

664  O-β-methylguanine DNA methyltransferase is upregulated in malignant transformation of gastric epithelial cells via its gene promoter DNA hypomethylation
Chen YX, He LL, Xiang XP, Shen J, Qi HY

678  RNA-Seq profiling of circular RNAs in human colorectal cancer 5-fluorouracil resistance and potential biomarkers

690  Cost-effective low-coverage whole-genome sequencing assay for the risk stratification of gastric cancer
Ye LP, Mao XL, Zhou XB, Wang Y, Xu SW, He SQ, Qian ZL, Zhang XG, Zhai LJ, Peng JB, Gu BB, Jin XX, Song YQ, Li SW
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>724</td>
<td>Clinical efficacy and prognostic risk factors of endoscopic radiofrequency ablation for gastric low-grade intraepithelial neoplasia</td>
<td>Wang NJ, Chai NL, Tang XW, Li LS, Zhang WG, Linghu EQ</td>
</tr>
<tr>
<td>734</td>
<td>SYSTEMATIC REVIEWS: Association of Blastocystis hominis with colorectal cancer: A systematic review of in vitro and in vivo evidences</td>
<td>Kumarasamy V, Atroosh WM, Anbazhagan D, Abdalla MMI, Azzani M</td>
</tr>
<tr>
<td>746</td>
<td>LETTER TO THE EDITOR: Re: Association between intestinal neoplasms and celiac disease - beyond celiac disease and more</td>
<td>Okumura K</td>
</tr>
</tbody>
</table>
ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Colm A O’Morain, AGAF, DSc, FACG, FRCP, MBChB, MD, MSc, Full Professor, Health Sciences, RCPI, Dublin Dublin 18, Ireland. colmomorain@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol)* is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
March 15, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerInfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerInfo/208

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerInfo/242

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Association of *Blastocystis hominis* with colorectal cancer: A systematic review of *in vitro* and *in vivo* evidences

Vinoth Kumarasamy, Wahib Mohammed Atroosh, Deepa Anbazhagan, Mona Mohamed Ibrahim Abdalla, Meram Azzani

**Abstract**

**BACKGROUND**
Recently, there have been several findings that showed intestinal colonisation of *Blastocystis hominis* (*Blastocystis*) as a risk factor to the worsening of colorectal cancer (CRC). However, studies have shown controversial results in the pathogenicity of *Blastocystis*.

**AIM**
To review systematically the evidence available on the association between CRC and *Blastocystis* and the prevalence of *Blastocystis* in CRC patients and to investigate cytopathic and immunological effects of *Blastocystis* in *in vitro* and *in vivo* studies.

**METHODS**
PRISMA guidelines were utilised in conducting this systematic review. Original
articles published before February 2, 2020 were included. PubMed, Science Direct, Scopus and Google scholar databases were searched. Manual searching was carried out to find articles missed during the online search.

RESULTS
Out of 12 studies selected for this systematic review, seven studies confirmed the prevalence of Blastocystis and found it to be between 2%-28% in CRC patients, whereby subtype 1 and subtype 3 were predominantly seen. A total of four studies employing in vitro human colorectal carcinoma cell line study models showed significant cytopathic and immunological effects of Blastocystis. In addition, one in vivo experimental animal model study showed that there was a significant effect of infection with Blastocystis on exacerbation of colorectal carcinogenesis.

CONCLUSION
Blastocystis is a commonly identified microorganism in CRC patients. These studies have provided supportive data that Blastocystis could exacerbate existing CRC via alteration in host immune response and increased oxidative damage. Future studies of CRC and Blastocystis should attempt to determine the various stages of CRC that are most likely to be associated with Blastocystis and its relationship with other intestinal bacteria.

Key Words: Blastocystis hominis; Colorectal cancer; Cytopathic effect; Immunological effect

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

INTRODUCTION

Blastocystis hominis (Blastocystis) is one of the most commonly recovered microorganisms in faecal specimens, and its widespread presence is found in colorectal cancer (CRC) patients[1]. Its distribution is known to be prevalent in both rural and urban areas[2]. This microorganism has been in discussion since early 1900s[3,4]; however, the taxonomic position of Blastocystis remains unanswered. Blastocystis treatment is often difficult due to its drug resistance and the failure of the host defenses to counter the infection[5]. Previous studies suggest that Blastocystis is a common and diverse element of microbiota in human host, as it has been highly prevalent in healthy individuals[6-8]. Blastocystis is commonly found in both patients with gastrointestinal symptoms and in healthy people widely across the world. More recently, researchers consider Blastocystis as an emerging zoonotic disease, and its pathogenic potential in human is somewhat controversial[9]. Although accumulating data suggest that Blastocystis is a pathogen, the pathogenic role in humans is still a matter of debate.

It is suggested that around 20% of cancer reported worldwide could have been due to infectious agents[10,11]. Viruses such as hepatitis B virus, human papilloma virus and Epstein-Barr virus have been associated with carcinogenesis. Various other bacteria also have been described previously to exacerbate cancer[12]. There are numerous epidemiological evidences that strongly support the fact that parasites can be a factor of various malignant tumours[13], but it is challenging to validate this relationship. Previously, a review article highlighted the correlation of various protozoan parasites including Blastocystis with carcinogenesis[13]. In addition, there was a case report in India that demonstrated a possible association of subtype 3 Blastocystis in the worsening of CRC[14].
There are a few other systematic reviews on the interventional studies done on Blastocystis, but we did not find any systematic reviews on the association between Blastocystis and CRC. Therefore, this systematic review aimed to (1) identify prevalence of Blastocystis in CRC patients; (2) review in vitro colorectal carcinoma cell line study models on the cytopathic and immunological effects of Blastocystis antigens; and (3) review an in vivo experimental animal model study to investigate the effect of infection with Blastocystis on exacerbation of colorectal carcinogenesis.

**MATERIALS AND METHODS**

PRISMA guidelines were utilised in conducting this review[15].

**Eligibility criteria**

Original articles that reported the prevalence and association of Blastocystis subtypes with CRC patients, in vitro studies using Blastocystis antigen and an in vivo study using an animal model published before February 2, 2020 were included.

**Exclusion**

Articles that reported the association of Blastocystis with cancer in general without specific findings on its association with CRC, reviews papers, conference proceedings and case reports were excluded from this review.

**Search**

PubMed, Science Direct, Scopus and Google scholar databases were searched. The various keywords used were: Blastocystis infection and CRC and their MESH terms and synonyms. Manual searching through reference lists of included journal articles was done to find the missed studies during online search.

**Study selection**

We identified 872 papers in the initial screening (Figure 1).

**Identification**

First, two authors developed a search strategy with different keywords and their synonyms. All articles were moved to the Endnote X7 software (Clarivate Analytics, Philadelphia, PA, United States), and 146 duplicate papers were removed. Two authors independently went through the titles and abstracts of the remaining 726 papers. Subsequently, a total of 22 papers were retained for full text review. The eligibility of retained papers was evaluated by two other authors. Authors checked the reference lists of all included articles for any relevant studies that met this systematic review inclusion criteria and had not been found during the database searches.

After full review of the 22 papers, 12 were selected. All authors have completed data extraction and agreed eligibility of included papers (Figure 1).

**Quality assessment**

For in vivo studies, the quality of the studies was assessed using Quasi experimental appraisal tool[16], which contained nine questions. For in vitro studies, checklist of Systematic Review Center for Laboratory Animal Experimentation’s Risk of Bias tool for assessing risk of bias as quality assessment was used[17]. The quality of all included studies was acceptable.

**Data extraction**

The data extracted included author-year, country, sampling, setting, methods, results and study conclusion (Table 1).

**RESULTS**

**Prevalence of Blastocystis in CRC patients**

Based on the seven reviewed articles, the prevalence of Blastocystis sp. in CRC patients were found to be between 2.8%-46.7%, whereby subtype 1 and subtype 3 were predominantly isolated.

A study by Esteghamati et al[35] evaluated the prevalence of Blastocystis in 85 cancer patients, including 39 CRC and 46 cancers outside gastrointestinal tract (COGT). In this study, Blastocystis was identified in 11/39 (28.2%) among CRC group. Another study in China by Zhang et al[18] showed the prevalence of Blastocystis in 4 among 49 (8.1%) patients with CRC. In another study conducted in Saudi Arabia, the prevalence of Blastocystis among CRC patients was 29.7%[19]. Subtype I was the
<table>
<thead>
<tr>
<th>No.</th>
<th>Ref.</th>
<th>Country</th>
<th>Sampling</th>
<th>Setting</th>
<th>Method</th>
<th>Main results</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Esteghamati et al[35], 2019</td>
<td>Tehran, Iran</td>
<td>Study design: cross-sectional. Study duration: July 2016 and November of 2017. Sample size (106): 80 patients (Primary Immunodeficiency), 85 (cancer patients) and 25 (organ transplant recipients)</td>
<td>3 hospitals in in Tehran, Iran</td>
<td>The aim of this study to determine the prevalence of intestinal parasites in 3 different groups of patients referred to 3 hospitals. Method used for parasite identification: Conventional methods, nested PCR and amplification of the 18S rRNA gene</td>
<td>The prevalence of Blastocystis hominis among CRC patient was 13/39 (28.2%)</td>
<td>The prevalence of Blastocystis hominis was found high in cancer patients, especially CRC patients</td>
</tr>
<tr>
<td>2</td>
<td>Zhang et al [18], 2017</td>
<td>China</td>
<td>Sample size: 381 faecal specimens were collected from cancer patients including CRC. Study duration: 2016 to 2017</td>
<td>Tumor Hospitalof Harbin Medical University</td>
<td>The aim of this study to determine the prevalence and genotypes/subtypes-Blastocystis in CP and analysed for the Blastocystis by PCR amplifying and sequencing</td>
<td>Prevalence of Blastocystis was 4 (8.1%) among CRC patient</td>
<td>Blastocystis subtype 1 and 3 have been identified in humans and animals</td>
</tr>
<tr>
<td>3</td>
<td>Mohamed et al [19], 2017</td>
<td>Saudi Arabia</td>
<td>Total sample size: 218. Two groups of participants: (1) CP (138) of which 74 had CRC and 46 had cancers outside gastrointestinal tract; and (2) NCP (80). Exclusion criteria: (1) Patient started chemotherapy regime; and (2) Receiving any anti-parasitic medication. Study duration: 2013-2015</td>
<td>King Abdullah Medical city (KAMC), Makkah</td>
<td>Case control study design: Aim, to determine the prevalence of Blastocystis among CRC patients compared to patients who had cancers outside gastrointestinal tract and control group. Obtained Blastocystis isolates were grouped into 2 categories (A and C), then subtyped into 3 various subtypes; subtype-I, subtype-II and subtype-V</td>
<td>Prevalence of Blastocystis among CRC = 22 (29%). Blastocystis infection frequency was significantly different between CP group and NC group. There was a higher probability of Blastocystis sp. among CP. Subtype I was the common subtype among CRC patients (54.5%). Interestingly, an association risk between Blastocystis subtype 1 with a greater risk of association in CRC group</td>
<td>The study revealed a probable association between subtype 1 of Blastocystis and CRC</td>
</tr>
<tr>
<td>4</td>
<td>Toychiev et al [20], 2018</td>
<td>Uzbekistan</td>
<td>A total sample of 400 participants, two groups of participants: (1) 200 CRC patients; and (2) 200 of Tashkent residents (without any gastrointestinal tract complaints). Exclusion criteria: (1) patient had problems with stool sample collection; and (2) received any treatment 2-3 wk before the study. Study duration: 2015-2017</td>
<td>Research Institute of Epidemiology, Microbiology and Infectious Diseases and the Research Center of Oncology, Tashkent, Uzbekistan, during the period</td>
<td>Study design: Prospective cohort: Prevalence of some parasites including Blastocystis sp. in CRC patients before and after surgery and chemotherapy. Methods: “3 stool samples for parasitological examination were taken at 2-d intervals during CRC diagnosis before and after surgery and chemotherapy”</td>
<td>A significantly higher prevalence of protozoa was found in CRC patients than in control population “the prevalence of Blastocystis in CRC patients is 4 times as high as in the control population. The overall prevalence of Blastocystis sp. was 2.8% and was higher than the other protozoa”</td>
<td>Data revealed a potential role for Blastocystis sp. in CRC pathogenesis</td>
</tr>
<tr>
<td>5</td>
<td>Kumarasamy et al[21], 2014</td>
<td>Malaysia</td>
<td>Sample size: 425 patients who go through diagnostic colonoscopy; faecal samples and colonic washouts were obtained from 221 control patients and 204 patients</td>
<td>University of Malaya Medical Centre</td>
<td>To determine the Blastocystis genotype present by comparing the prevalence using colonic washouts and faecal samples PCR and standard stool culture. Both techniques were used to detect Blastocystis from control and</td>
<td>The prevalence of Blastocystis was 15.29% (65/425). “Colonic washouts and faecal samples showed 12.24% (n = 52) and 5.65% (n = 24) of Blastocystis infection respectively”. A total of 43 individuals were positive for Blastocystis in CRC patients and</td>
<td>Blastocystis sp. is common in CRC patients. Subtype 3 is the most common genotype in the infected individuals</td>
</tr>
<tr>
<td>Study Details</td>
<td>Country</td>
<td>Sample</td>
<td>Study Duration</td>
<td>Methodology</td>
<td>Results/Findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>--------</td>
<td>----------------</td>
<td>-------------</td>
<td>-----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chandramathi et al. [1], 2012</td>
<td>Malaysia</td>
<td>Stool samples were obtained from 46 and 15 breast cancer and CRC patients, respectively. Department of Parasitology, Faculty of Medicine, University of Malaya</td>
<td>Aim: To investigate whether intestinal parasites can be an opportunistic infection in breast cancer and CRC patients who are undergoing chemotherapy treatment. Molecular detection of microsporidia species was done using a PCR technique. The presence of <em>Blastocystis hominis</em> was further confirmed by culturing stool samples.</td>
<td>Patients with CRC. was significantly higher compared to control group. Subtype 3 was predominant compared to other subtypes. It was significantly higher in CRC group as compared with control group.</td>
<td><em>Blastocystis hominis</em> and microsporidia could appear as opportunistic infections during chemotherapy treatment of CP. This infection may diminish the efficacy of chemotherapy treatments and consequently advance the progression of cancer.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Majeed et al. [22], 2019</td>
<td>Iraq</td>
<td>116 faecal specimens with <em>Blastocystis</em> and <em>Helicobacter pylori</em> infection, 15 biopsy specimens from CRC patients. Middle Technical University/Baghdad 1st Feb 2018-15th June 2018</td>
<td>Faecal specimens were screened for <em>Blastocystis</em> and <em>Helicobacter pylori</em>. Direct DNA sequencing was done to evaluate mutations in CRC-associated molecular pathways.</td>
<td>Prevalence of <em>Blastocystis</em> infection statistically insignificant in various age groups. Prevalence of <em>Blastocystis</em> infection was more in females [females 29 (46.9 %), males 22(43.1%)] Prevalence of mixed infection ( <em>Blastocystis</em> and <em>Helicobacter pylori</em>) was 27 (25.32%).</td>
<td>Prevalence of <em>Blastocystis</em> infection was more in females. <em>KRAS</em> and <em>TP53</em> gene mutation was observed in the CRC patients with mixed infection ( <em>Blastocystis</em> and <em>H. pylori</em>)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chan et al. [23], 2012</td>
<td>Malaysia</td>
<td>In vitro study model. PBMCs were isolated from blood collected from healthy persons. Solubilised antigen of <em>Blastocystis</em> isolate was obtained from a human subject. Human colorectal carcinoma cell line, HCT116, was used. University of Malaya, Kuala Lumpur</td>
<td>Effect solubilised antigen of <em>Blastocystis</em> on the HCT116 proliferation quantified. Gene expressions of certain genes in HCT116 and PBMCs evaluated via real-time reverse transcription PCR. PBMCs were isolated from blood using Histopaque technique. Cell proliferations were measured using MTT assay.</td>
<td>Increased number of PBMCs/ HCT116 cells observed with <em>Blastocystis</em> antigen. IFN-γ and TNF-α were downregulated and IL-6, IL-8 and NF-κB, p53 were upregulated in the PBMCs treated with the antigen. IFN-γ was downregulated and IL-6 and NF-κB was upregulated in HCT116 cells.</td>
<td>Solubilised antigen of <em>Blastocystis</em> could facilitate increased number of PBMCs/ HCT116 cell and has the ability to downregulate immune cell responses.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kumarasamy et al. [24], 2013</td>
<td>Malaysia</td>
<td>In vitro study model using HCT116 treated with solubilised <em>Blastocystis</em> antigen from 5 <em>Blastocystis</em> subtypes. University Malaya research Lab</td>
<td>In vitro study. HCT116 treated with solubilised antigen from <em>Blastocystis</em>. Following Assays: Proliferation of the cell line, HCT116 on exposure to different <em>Blastocystis</em> subtypes; Gene expression profile of apoptotic genes like p53 and CTSB; Transcription factor gene expression profile</td>
<td><em>Blastocystis</em> subtypes (5) increased the proliferation of HCT116, especially subtype 3. <em>Blastocystis</em> antigen caused the upregulation of Th2 and Th1 cytokines, and downregulation of IFN-γ and p53 in HCT116 cells. <em>Blastocystis</em> antigen caused a higher stimulation of gene expression of CTSB and TGFB-β genes.</td>
<td>Infection with <em>Blastocystis</em> caused exacerbation of existing colon cancer cells. The effect may be due to weakening of the cellular immune response and dysregulation of IFN-γ and p53 expression. Infection with <em>Blastocystis</em> subtype 3 has a higher pathogenic potential.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Source</td>
<td>Country</td>
<td>Study Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Ahmed et al [25], 2019 | Cairo, Egypt | Seven *Blastocystis* isolates were from stools specimen from patients with early diagnosed CRC (Oncology and Surgery and Colonoscopy unit) of a Hospital in Egypt. The different groups were: Group I (GI), 12 isolates from infected non-CRC; Group II (GII), 6 from infected symptomatic patients and Group III (GIII), 6 from infected non-symptomatic carriers. Aim: To investigate some phenotypic characters like surface ultrastructure, protein profiles and protease activity of *Blastocystis* from three different clinical groups. Techniques performed: Scanning electron microscopy to study morphology of the organism; SDS-PAGE to analyse the *Blastocystis* protein profiles and their protease activities. Observations: All CRC *Blastocystis* isolates showed a very rough intensely folded surface when compared to less rough and smooth surface of isolates from symptomatic and asymptomatic and non-CRC isolates; SDS-PAGE showed presence of 2 protein bands of 250 and 32 KDa in 42.9% of *Blastocystis* CRC isolates and these proteins were absent in Non-CRC isolates. When the protease activity of the parasite was tested, no significant difference existed between isolates of the three groups. There was significant difference in the surface structure and the protein profiles between different clinical isolates of *Blastocystis*. Differences indicate that it may be: (1) secondary to the altered gut environment in the presence of CRC or (2) indicators of a different pathogenic potential of the parasite in inducing malignancy.

| Kumarasamy et al [26], 2017 | Malaysia | Different specimens collected: Blood, urine, faecal samples and gastrointestinal tract sections from 24 male Wistar rats. Age of the rats: 3 wk. Weight of each rat: Average of 65 g/rat. University Malaya research Lab | In vivo experimental study. Aim: To investigate the effect of infection with *Blastocystis* cyst on exacerbation of carcinogenesis. Twenty-four rats divided into different groups for the study (4 groups, 6 rats each): Control group, AOM group, group inoculated with *Blastocystis* cyst, the group inoculated with *Blastocystis* cyst and AOM injection. Body weights recorded once a week. Rat faecal samples screened for presence of *Blastocystis* post-inoculation. Histopathological assessment of the rat colon for aberrant crypts. Urine and blood samples assessed for oxidative stress. Observations: lower body weight showed by *Blastocystis* infected rats than rats infected with *Blastocystis* and injected with AOM (P < 0.05). Stools from AOM-rats with *Blastocystis* infection were softer and watery compared to the AOM-rats without *Blastocystis* infection. *Blastocystis* was present in the stool of all infected rats from Day 3 to 7 post-inoculation. All the rats injected with AOM developed numerous abnormal, hyperplastic colonic crypts. Co-administration of *Blastocystis* cyst showed a 1.6-fold increase in the number of crypts when compared with control rats treated with AOM only. Two of the co-*Blastocystis* infected AOM-rats were found to have adenomas. Major dysplasia and presence of hyperplastic aberrant crypts were observed in rats injected with AOM and co-infected with *Blastocystis*. *Blastocystis* infection considerably enhanced the AOM-induced carcinogenesis because of the oxidative damage of the intestinal epithelium.|

AOM: Azoxymethane; CP: Cancer patients; CRC: Colorectal cancer; CTSB: Cathepsin B; IFN: Interferon; IL: Interleukin; NCP: Non cancer patients; NF-kB: Nuclear factor kappa B; PBMCs: Peripheral blood mononuclear cells; PCR: Polymerase chain reaction; SDS-PAGE: Sodium dodecyl sulphate-polyacrylamide gel electrophoresis.

predominant (54.5%) among CRC patients, while subtype II was predominant (43.7%) among COGT patients [19]. Higher prevalence of intestinal helminths and protozoa was observed in CRC patients than in the control population in a study conducted in Uzbekistan. The prevalence of *Blastocystis* in CRC patients was four times higher than that in the control population. The overall prevalence of *Blastocystis* (2.8%) was significantly higher than the other protozoa [20]. In a study by Kumarasamy et al [21] in Malaysia, among 221 control patients and 204 CRC patients with colorectal malignancies, the overall prevalence of *Blastocystis* infection was 15.29% (65/425). A total of 43 (21.08%) samples were positive for *Blastocystis* infection in CRC patients and was significantly higher compared to normal individuals (n = 22, 9.95%, P < 0.01). Subtype 3 was present at higher levels compared to other subtypes detected in both groups and was significantly higher in CRC patients as compared with control patients [21]. Another study was designed to investigate the emergence of *Blastocystis* and Microsporidia infections in breast and CRC patients undergoing chemotherapy treatment. This study found that 7 out of 15 CRC
patients were positive Blastocystis in various chemotherapy cycles, accounting for 46.7%. However, the researchers did not mention whether the isolate was from the same patients in different cycles[1]. In a study carried out in Iraq, stool samples from 116 patients with Blastocystis and H. pylori infections were investigated. Fifteen tissue samples of CRC were taken from 15 suspected patients out of 116 infected cases, and it was shown that the infection with Blastocystis and H. pylori was associated with pathological gene mutation in the CRC patients[22].

In vitro colorectal carcinoma cell line studies on the cytopathic and immunological effects of Blastocystis antigen

Three of the reviewed articles used in vitro study models and observed considerable cytopathic and immunological effects induced by the solubilised antigen of Blastocystis to the human colorectal carcinoma cell line[7,23,24]. These findings speculated that Blastocystis infection may enhance the proliferation, invasiveness and metastatic properties of CRC cells. One study investigated some phenotypic characteristics of Blastocystis isolated from CRC patients[25].

The three in vitro model studies used the human colorectal carcinoma cell line HCT116 and the Blastocystis isolated from a human subject[7,23,24]. One of the studies demonstrated the cytopathic effect of Blastocystis antigen on peripheral blood mononuclear cells. This study findings showed increased cell proliferations in Blastocystis antigen-stimulated HCT116 cell-lines, which suggested that the infection by Blastocystis may facilitate the growth of colon cancer cells[7]. Another in vitro study showed that the five subtypes of Blastocystis significantly increased the proliferation of HCT116, especially subtype 3. Blastocystis antigen caused the upregulation of T helper (Th)2 and Th1 cytokine gene expressions, and downregulation of interferon gamma and p53 gene expressions in HCT116 cells. In addition, Blastocystis antigen caused a significantly higher stimulation of Cathepsin B (CTSB) and Transforming growth factor beta (TGF-β) gene expression, which indicates the pathogenic potential of this protozoan[24].

Another study showed an increase in cell proliferation in HCT116 cells inoculated with the symptomatic Blastocystis antigen. Gene expression studies carried out in this research also showed a significant upregulation of Th2 cytokines, which indicates the parasites’ potential in weakening the cellular immune response[23]. HCT116 cells exposed to symptomatic and asymptomatic Blastocystis antigen caused a significant upregulation of CTSB, which led to the postulation that the Blastocystis antigen may enhance the invasive and metastasis properties of CRC[23].

Another study sought to investigate some phenotypic characteristics such as the surface ultrastructure, protein profiles and protease activity of Blastocystis isolated from three different clinical groups: CRC patients, non-CRC symptomatic and asymptomatic infected persons. This study showed the presence of two protein bands of 230 and 32 KDa in 42.9% of Blastocystis CRC isolates with their complete absence from non-CRC isolates. There was no significant difference in the protease activity of the protein among isolates of the three groups, CRC and Non-CRC Blastocystis isolates[25].
In vivo experimental animal model to investigate the effects of infection with Blastocystis on exacerbation of colorectal carcinogenesis

An animal model study compared the effects of Blastocystis infected rats and rats infected with Blastocystis co-administered with Azoxymethane (AOM), a potent carcinogen. This finding showed that the co-administration of Blastocystis cyst resulted in a 1.6-fold increase in the number of colonic crypts when compared with control rats treated with AOM only. Two of the co-Blastocystis infected AOM rats were found to have adenomas. Major dysplasia and the presence of hyperplastic aberrant crypts were also observed in rats injected with AOM and co-infected with Blastocystis[26].

DISCUSSION

Blastocystis is one of the most common gut microorganisms found in healthy individuals[27]. Besides being associated with a healthy gut microbiota[27,28], Blastocystis infection is also known to be opportunistic in immunocompromised patients[29]. CRC is the third most common cancer diagnosed worldwide and one of the major causes of cancer-associated fatality[30]. The reason for high mortality is due to the asymptomatic progression of the disease that usually results in late diagnosis[31,32]. Certain gut microorganisms are known to be one of the important factors that had been associated with initiation and development of CRC[33]. However, data on the roles of parasites are vague and restricted. Various findings have been reported regarding the association between Blastocystis among CRC patients, whereby positive association was shown in all the studies[1,23,24]. Therefore, the aim of this systematic review was to quantify the studies published so far that revealed the direct association of Blastocystis and CRC. This paper outlines the results of a systematic review to evaluate the prevalence of Blastocystis in CRC patients, in vitro studies using Blastocystis antigen and an in vivo study using animal models.

Out of the data extracted from 12 studies relevant to this topic, all the studies showed positive association between Blastocystis and CRC. Prevalence studies, in vitro investigations and in vivo studies were used to evaluate the pathogenicity of Blastocystis with CRC. The global prevalence of Blastocystis infection ranged from 1.5%-20% in developed countries, which was much less than that in developing countries, which was 30%-50%[34]. Based on our review, the prevalence of Blastocystis infection in CRC patients ranged between 2.8%-46.7%. It has been widely reported in the world, in developing countries such as Iran, China, Saudi Arabia, Uzbekistan and Malaysia[18-20,24,35]. The first demonstration of Blastocystis infection in Iran was reported in 11 CRC patients in Tehran province[35]. In Malaysia, a total of 43 samples were positive for Blastocystis from 204 CRC patients[21]. This study utilised colonic washout in addition to stool sample to recover the parasites. Subtype 3 Blastocystis was detected predominantly as compared to other subtypes[21]. Some of these findings highlighted the high prevalence of certain subtypes of Blastocystis among these patients[19,21]. A previous study showed that subtype 1 was the most common genotype identified (54.5%) among CRC patients[19]. DNA was extracted from Blastocystis cultures via conventional method and subtyped using multiplex polymerase chain reaction (PCR) with restriction fragment length polymorphism and sequence-tagged site primers-based PCR. In another study, subtype 3 was predominant compared to other subtypes found in both CRC patients and healthy individuals[21]. Subtype 3 is speculated as the most pathogenic subtype in symptomatic individuals[36]. Some researchers have attributed subtype 3 to be more pathogenic compared to other subtypes[37,38]. Blastocystis was initially screened via in vitro culture and conventional PCR using stool samples and colonic washouts. The presence of Blastocystis infection in CRC patients could be contributed by various reasons including health status. For instance, positive cases were more likely in patients with gastrointestinal symptoms compared to healthy individuals[18]. Besides, Blastocystis was also identified in higher frequency in immunosuppressed CRC patients who were undergoing chemotherapy treatment[1,18].

A total of three in vitro studies were carried out using colorectal carcinoma cell line models to study cytopathic and immunological effects of Blastocystis antigen[7,23,24]. Some of the research studies suggested that solubilised antigen of Blastocystis could facilitate the exacerbation of CRC cells, HCT116[7,23]. In another study by Kumarasamy et al[24], Blastocystis subtype 3 stimulated significantly higher CTSB and TGF-β gene expression in HCT116, which indicates the pathogenic potential of this protozoan. Result of in vitro studies that were performed in Malaysia were similar[7,23,24]. Blastocystis is commonly found in both patients with gastrointestinal symptoms and in healthy people widely across the world. More recently, researchers consider Blastocystis as an emerging zoonotic disease, and its pathogenic potential in human is unclear[9]. The pathogenic potential of Blastocystis was widely debated, as they are found in both symptomatic and asymptomatic patients. The significant expression of nuclear factor kappa light chain enhancer of activated B cells was observed in HCT116 exposed to Blastocystis antigen isolated from individuals with gastrointestinal symptoms, but such observations were not found when the colon cells treated with Blastocystis antigen isolated from asymptomatic individuals. This finding shows the potential pathogenicity of symptomatic Blastocystis in CRC patients[23]. Similarly, HCT116 cells exposed to symptomatic and asymptomatic Blastocystis
antigen caused a significant upregulation of CTSB. These gene expression findings lead to a postulation that the Blastocystis antigen may enhance the invasive and metastasis properties of CRC\textsuperscript{[23]}. Besides, proliferation of HCT116 when exposed with Blastocystis antigen could be a result of higher levels of interleukin (IL)-6 and IL-8 expression\textsuperscript{[23]}.

Another study revealed that solubilised antigen isolated from subtype 2 and 3 isolates introduced to colon cancer cells showed significant IL-8 and IL-6 expression\textsuperscript{[24]}. The production of inflammatory cytokines such as IL-8 together with reactive oxygen species could contribute to the pathogenesis of cancer\textsuperscript{[38]}. In a few studies conducted previously, IL-6 expression was associated with proliferation of colon carcinoma\textsuperscript{[39,40]}. Besides that, subtype 3 Blastocystis also triggered positive expression of CTSB in cancer cells. A previous study showed that CTSB expression is significant in CRC patients\textsuperscript{[41]}.

Only one study was conducted to investigate the in vivo effect of Blastocystis in Wistar rats. In parallel with in vitro studies, an in vivo study showed similar findings on the possible role of Blastocystis to exacerbate CRC. The results demonstrated that Blastocystis may cause damage to the intestinal mucosal layer and result in increased crypts formation. Furthermore, an increased oxidative stress was also observed in these rats. There have been numerous animal models of human CRC and animal model of tumour carried out via quantification of aberrant crypt foci\textsuperscript{[42,43]}. This allows the study of gut microbiome and its role in pathogenesis. In humans, there are many potential pathogenic and non-pathogenic gut microbial infections, and various animal models have been used for such studies. Aberrant crypt foci are known as putative precancerous lesions of the colon in both animal models and humans\textsuperscript{[44,45]}. Even though various studies associating Blastocystis and CRC were carried out via in vitro model using colon cancer cells, this study utilised animal model to bridge between in vivo findings in the laboratory and studies in humans. As such, this extensive in vivo study showed that Blastocystis had a major impact on normal intestinal function in Wistar rats resulting in damage to the intestinal mucosal layer and inducing oxidative stress, which caused increase in crypts formation in AOM-treated rats. The study establishes that Blastocystis is a pathogen, and there is a need to screen cancer patients for harbouring this parasite.

This systematic review has some limitations. According to these investigations, a greater prevalence of Blastocystis was found in CRC patients, but the question whether increased prevalence of Blastocystis could be linked with increased high risk to CRC is unclear. The studies discussed in this review did not highlight the association of Blastocystis according to cancer stages, and it was unclear if Blastocystis itself could result in the initiation of malignancy as Blastocystis acquisition alone is insufficient for cancer development. Even though strong association between Blastocystis and CRC is apparent, some questions remain unanswered. Therefore, we propose future studies should focus on the pathogenicity of Blastocystis in various stages of CRC by concentrating on the molecular pathways involved in tumorigenesis.

CONCLUSION

In conclusion, according to various recent studies, Blastocystis is one of the most commonly identified microorganisms in CRC patients, whereby subtype 1 and subtype 3 were predominantly isolated. It is apparent in most cases that the prevalence is higher in developing countries compared to developed countries. These studies have provided supportive data that Blastocystis could exacerbate existing CRC via alteration in host immune response and increased oxidative damage. An in vivo study well-established that Blastocystis infections resulted in tissue damage from host inflammatory responses that may predispose the host towards neoplasm exacerbation. Upregulation of gene expression responsible for proinflammatory cytokines and downregulation of apoptotic genes was observed in in vitro studies. Through continued research in Blastocystis and CRC, we may discover new findings as well as develop new effective means of prevention. Future studies of CRC and Blastocystis should attempt to determine the various stages of CRC that are most likely to be associated with Blastocystis and its association with other intestinal bacteria. In addition, future in vivo studies should evaluate exposure to various subtypes of Blastocystis.

ARTICLE HIGHLIGHTS

Research background

Intestinal colonisation of Blastocystis hominis (Blastocystis) as a risk factor to the worsening of colorectal cancer (CRC).

Research motivation

There has been an increase in the prevalence of Blastocystis in CRC patients. Besides, various in vitro and in vivo studies have highlighted Blastocystis as an important risk factor for the worsening of CRC.
Research objectives
To perform a systematic review on all evidence on the association between CRC and Blastocystis.

Research methods
A systematic review of the literature was performed by searching PubMed, Science Direct, Scopus and Google scholar databases up to February 2020.

Research results
Out of 12 studies selected for this systematic review, seven studies have confirmed the prevalence of Blastocystis. A total of four studies employing in vitro human colorectal carcinoma cell line study models showed significant cytopathic and immunological effects of Blastocystis. One in vivo experimental animal model study showed that there was a significant effect of infection with Blastocystis on exacerbation of colorectal carcinogenesis.

Research conclusions
Blastocystis is a commonly identified microorganisms in CRC patients. These studies have provided supportive data that Blastocystis could exacerbate existing CRC via alteration in host immune response and increased oxidative damage.

Research perspectives
Future studies of CRC and Blastocystis should attempt to determine the various stages of CRC that are most likely to be associated with Blastocystis and its association with other intestinal diseases.

FOOTNOTES
Author contributions: Azzani M designed the research, performed the literature search and extracted the data; Kumarasamy V wrote the discussion and extracted the data; Atroosh WM wrote the methodology and extracted the data; Anbazhagan D wrote the results and extracted the data; Abdalla M wrote the introduction and extracted the data; All authors read and approved the final manuscript.

Conflict-of-interest statement: Dr. Azzani has nothing to disclose.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Malaysia

ORCID number: Vinoth Kumarasamy 0000-0002-8895-1796; Wahib Mohammed Atroosh 0000-0003-3809-3460; Deepa Anbazhagan 0000-0002-2527-4126; Mona Mohamed Ibrahim Abdalla 0000-0002-4987-9517; Meram Azzani 0000-0002-7939-1539.

S-Editor: Chang KL
L-Editor: Filipodia
P-Editor: Chang KL

REFERENCES
3 Brumpt E. Blastocystis hominis n. sp. et formes voisines. Bull Soc Pathol 1912; 5: 725-730
Kumarasamy V et al. Association of Blastocystis with colorectal cancer


28 Audubert C, Even G, Cian A; Blastocystis Investigation Group, Loywick A, Merlin S, Visconti G; Chabé M. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of gut human bacterial microbiota. Sci Rep 2016; 6: 25255 [PMID: 27147260 DOI: 10.1038/srep25255]


Kumarasamy V et al. Association of Blastocystis with colorectal cancer


